We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The vast majority of drug recalls in the past 10 years have been triggered by cardiovascular safety issues, which must be managed by doing a thorough QT study (TQTS) early in the clinical trial of any new compound, according to Daniel Goodman, director of medical affairs for Covance Cardiac Safety Services.